If the Indian court had allowed the Glivec patent, it would have paved the way to patenting many other drugs for HIV/AIDS and other ailments now produced cheaply in India as generics, said Tahir Amin, co-founder of the Initiative for Medicines, Access and Knowledge. “This is more than just this particular drug – it affects all the other cases going on” in India, Amin said. Even beyond Indian courts, “some countries will look at this and take strength from the fact that India has stood its ground.”
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.